Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Poor social support and loneliness in chronic headache: Prevalence and effect modifiers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reply: The role of neurovascular contact in patients with multiple sclerosis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. The chronobiology of migraine: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: This post-hoc analysis was conducted to evaluate the effect of erenumab on monthly migraine days, monthly migraine attacks, and attack duration in patients with episodic migraine to investigate whether erenumab actually prevents the occurrence of migraine attacks and/or shortens them.

METHODS: We conducted a post-hoc analysis of the data from the STRIVE study, in 955 patients with episodic migraine. Relative changes from baseline to mean over months 4, 5 and 6 of the double-blind treatment phase in monthly migraine days, monthly migraine attacks and mean migraine attack duration were assessed.

RESULTS: Erenumab reduced monthly migraine days and monthly migraine attacks compared with placebo in a similar way. Erenumab had only a minor impact on shortening the duration of migraine attacks.

CONCLUSION: These post-hoc analyses demonstrate that the decrease in monthly migraine days by erenumab is mainly driven by a reduction in the frequency of monthly migraine attacks and to a much lesser extent by shortening the duration of migraine attacks.Trial registration: This study is registered at ClinicalTrials.gov (NCT02456740).

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind41
Udgave nummer11-12
Sider (fra-til)1262-1267
Antal sider6
ISSN0333-1024
DOI
StatusUdgivet - okt. 2021

ID: 65607335